CA2278757A1 - 5-aminoalcoxy-1,4-dihydroquinoxaline-2,3-diones en tant qu'agonistes de la dopamine - Google Patents

5-aminoalcoxy-1,4-dihydroquinoxaline-2,3-diones en tant qu'agonistes de la dopamine Download PDF

Info

Publication number
CA2278757A1
CA2278757A1 CA002278757A CA2278757A CA2278757A1 CA 2278757 A1 CA2278757 A1 CA 2278757A1 CA 002278757 A CA002278757 A CA 002278757A CA 2278757 A CA2278757 A CA 2278757A CA 2278757 A1 CA2278757 A1 CA 2278757A1
Authority
CA
Canada
Prior art keywords
halogen
alkoxy
hydrogen
alkyl
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002278757A
Other languages
English (en)
Inventor
Uresh Shantilal Shah
Richard Eric Mewshaw
James Albert Nelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2278757A1 publication Critical patent/CA2278757A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des composés de la formule (I) dans laquelle R?1¿ et R?2¿ sont sélectionnés indépendamment entre l'hydrogène, un groupe alkyle à chaîne droite et ramifiée présentant jusqu'à dix atomes de carbone ou -(CH¿2?)¿m?Ar où Ar représente phényle, naphtyle ou thiényle, chacun facultativement substitué par un ou deux substituants sélectionnés indépendamment entre alkyle C¿1?-C¿6?, halogène, alcoxyde C¿1?-C¿6? et trifluorométhyle; ou NR?1¿R?2¿ représente 1,2,3,4-tétrahydroquinoline-1-yl ou 1,2,3,4-tétrahydroisoquinoline-2-yl; m est compris entre 1 et 5; n représente 1 ou 2; Y représente halogène, alkyle C¿1?-C¿6? et alcoxy C¿1?-C¿6?; ou leurs sels pharmaceutiquement acceptables, lesquels constituent des agonistes de la dopamine D¿2? et sont par conséquentes utiles dans le traitement de psychoses et de la maladie de Parkinson's.
CA002278757A 1997-02-18 1998-01-13 5-aminoalcoxy-1,4-dihydroquinoxaline-2,3-diones en tant qu'agonistes de la dopamine Abandoned CA2278757A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80132497A 1997-02-18 1997-02-18
US08/801,324 1997-02-18
PCT/US1998/001170 WO1998035948A1 (fr) 1997-02-18 1998-01-13 5-aminoalcoxy-1,4-dihydroquinoxaline-2,3-diones en tant qu'agonistes de la dopamine

Publications (1)

Publication Number Publication Date
CA2278757A1 true CA2278757A1 (fr) 1998-08-20

Family

ID=25180799

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002278757A Abandoned CA2278757A1 (fr) 1997-02-18 1998-01-13 5-aminoalcoxy-1,4-dihydroquinoxaline-2,3-diones en tant qu'agonistes de la dopamine

Country Status (14)

Country Link
EP (1) EP0963372A1 (fr)
JP (1) JP2001511805A (fr)
KR (1) KR20000071162A (fr)
CN (1) CN1248249A (fr)
AR (1) AR011669A1 (fr)
AU (1) AU722616B2 (fr)
BR (1) BR9807230A (fr)
CA (1) CA2278757A1 (fr)
HU (1) HUP0001311A3 (fr)
IL (1) IL131160A0 (fr)
NZ (1) NZ336971A (fr)
TW (1) TW434230B (fr)
WO (1) WO1998035948A1 (fr)
ZA (1) ZA981306B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2285786E (pt) 2008-06-16 2014-01-07 Merck Patent Gmbh Derivados de quinoxalinediona

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179551C (no) * 1987-11-10 1996-10-30 Novo Nordisk As Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser
DK715888D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
US4975430A (en) * 1989-06-16 1990-12-04 The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University CNQX and its analogs as therapeutics for degenerative neural diseases
PT99864B (pt) * 1990-12-21 1999-06-30 Schering Ag Processo para a preparacao de novas composicoes farmaceuticas contendo antagonistas de receptor de quisqualato
US5159083A (en) * 1990-12-28 1992-10-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; a class of dopamine receptor subtype specific ligands
DK0647137T3 (da) * 1992-06-22 2008-12-08 State Of Oregon Through Oregon Glycinreceptorantagonister og anvendelse deraf
GB9419318D0 (en) * 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
PT707007E (pt) * 1994-10-14 2002-06-28 Merck Patent Gmbh Derivados amino(tio)eter como agentes activos no snc
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists

Also Published As

Publication number Publication date
BR9807230A (pt) 2000-04-25
CN1248249A (zh) 2000-03-22
IL131160A0 (en) 2001-01-28
WO1998035948A1 (fr) 1998-08-20
EP0963372A1 (fr) 1999-12-15
JP2001511805A (ja) 2001-08-14
NZ336971A (en) 2000-10-27
ZA981306B (en) 1999-08-17
TW434230B (en) 2001-05-16
AU722616B2 (en) 2000-08-10
AU6035098A (en) 1998-09-08
KR20000071162A (ko) 2000-11-25
AR011669A1 (es) 2000-08-30
HUP0001311A2 (hu) 2001-05-28
HUP0001311A3 (en) 2001-07-30

Similar Documents

Publication Publication Date Title
EP0923548B1 (fr) 4-aminoethoxy indoles utilises en tant qu'agonistes du recepteur d2 de la dopamine et en tant que ligands des recepteurs 5ht 1a
EP0923551B1 (fr) Derives de 4-aminoethoxy indolone
AU722616B2 (en) 5-aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones being dopamine agonists
US5922715A (en) 5-aminoalkoxy-1, 4-dihydroquinoxaline-2, 3-diones
US5958965A (en) 4-aminoethoxy indoles
US6127380A (en) 4-aminoalkoxy-1H-benzoimidazoles
US5817690A (en) 4-aminoethoxy indolone derivatives
EP0923576B1 (fr) Derives de 4-aminoethoxy-indolone utilises en tant qu'agonistes du recepteur d2 de la dopamine
US5972958A (en) 4-aminoalkoxy-1,3-dihydro-benzoimidazol-2-thiones
US5872144A (en) 4-aminoethoxyindazole derivatives
WO1999052870A1 (fr) 4-amino-(ethylamino)-oxindoles utilises comme agonistes des autorecepteurs de la dopamine
CA2278700A1 (fr) Derives de 4-aminoalcoxy-1h-benzimidazole, leur preparation et leur utilisation comme agonistes des autorecepteurs de la dopamine (d2)
MXPA99007593A (en) 5-aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones being dopamine agonists
US5760070A (en) 4-Aminoethoxy indolone derivatives
CA2278718A1 (fr) Derives de 4-aminoalcoxy-1,3-dihydrobenzoimidazol-2-thiones, leur preparation et leur utilisation en tant qu'agonistes d'autorecepteur de la dopamine (d2)
US5990144A (en) 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one dopamine autoreceptor agonists
CA2278746A1 (fr) Derives du 4-aminoethoxyindazole
US6228880B1 (en) 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
AU744443B2 (en) 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one derivatives, their preparation and their use as dopamine autoreceptor (D2) agonists
MXPA99007586A (en) 4-aminoalkoxy-1h-benzimidazole derivatives, their preparation and their use as dopamine autoreceptor (d2
MXPA99007587A (en) 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-thiones derivatives, their preparation and their use as dopamine autoreceptor (d2) agonists
MXPA99007591A (en) 4-aminoethoxyindazole derivatives
MXPA99007585A (en) 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one derivatives, theirpreparation and their use as dopamine autoreceptor (d2) agonists

Legal Events

Date Code Title Description
FZDE Discontinued